HPV vaccine transforms the scenario and practically eliminates the risk of deaths from cervical cancer in young people in England

The introduction of regular immunization against the human papillomavirus (HPV) in England resulted in an almost complete reduction in the risk of fatalities from cervical cancer in young women, according to a new scientific survey. Researchers reported in the renowned medical journal “The Lancet” that, between 2020 and 2024, no young woman aged between 20 and 24 died as a result of this neoplasm in England. This achievement suggests that the HPV vaccination campaign may have prevented the loss of almost 200 lives in the period analyzed.
This is the first time that no cases of death from this specific type of cancer have been recorded in the age group investigated within the country. The same study revealed that the number of deaths from cervical cancer in this age cohort had already shown a significant drop of 80% between 2015 and 2019, showing a positive trend.
“Thanks to HPV vaccination and cervical cancer screening programmes, a future in which virtually no one else develops this disease is now clearly within our reach,” said Michelle Mitchell, representative of Cancer Research UK, highlighting the impact of health initiatives.
The human papillomavirus, known as HPV, is a sexually transmitted infectious agent that can lead to the development of cervical cancer, as well as other types of cancer in the mouth and throat, female and male genitalia, and the anus. Routine vaccination against HPV was initially implemented in the United Kingdom in 2008 for adolescent girls, being extended to boys in 2019. The study indicates that adolescents immunized against the virus between the ages of 12 and 13 have a practically non-existent risk of dying from cervical cancer before they turn 30.
In Germany, the Standing Committee on Vaccination (STIKO) recommends immunization against HPV for children aged between 9 and 14 years, although application may occur at later stages. However, data from health insurer Barmer revealed that by autumn 2024, only around 55% of teenage girls and 42% of teenagers had received at least one dose of a vaccine against the virus. This disparity in vaccination rates between countries shows the potential of the public health campaign, but also the challenges in the population’s adherence to achieving the eradication of cervical cancer.






